Literature DB >> 31693134

Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?

Adam Brufsky1, Aju Mathew2.   

Abstract

Entities:  

Year:  2020        PMID： 31693134      PMCID： PMC7357314          DOI： 10.1093/jnci/djz216

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  12 in total

Review 1.  Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Sukhbinder Dhesy-Thind; Glenn G Fletcher; Phillip S Blanchette; Mark J Clemons; Melissa S Dillmon; Elizabeth S Frank; Sonal Gandhi; Rasna Gupta; Mihaela Mates; Beverly Moy; Ted Vandenberg; Catherine H Van Poznak
Journal:  J Clin Oncol       Date:  2017-03-06       Impact factor: 44.544

2.  De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Authors:  G Curigliano; H J Burstein; E P Winer; M Gnant; P Dubsky; S Loibl; M Colleoni; M M Regan; M Piccart-Gebhart; H-J Senn; B Thürlimann
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

3.  Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

Authors:  Alexander H G Paterson; Stewart J Anderson; Barry C Lembersky; Louis Fehrenbacher; Carla I Falkson; Karen M King; Lorna M Weir; Adam M Brufsky; Shaker Dakhil; Thomas Lad; Luis Baez-Diaz; Julie R Gralow; André Robidoux; Edith A Perez; Ping Zheng; Charles E Geyer; Sandra M Swain; Joseph P Costantino; Eleftherios P Mamounas; Norman Wolmark
Journal:  Lancet Oncol       Date:  2012-06-14       Impact factor: 41.316

4.  Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.

Authors:  Robert Coleman; Andrew Hall; Joan Albanell; Andrew Hanby; Richard Bell; David Cameron; David Dodwell; Helen Marshall; Joël Jean-Mairet; Juan-Carlos Tercero; Federico Rojo; Walter Gregory; Roger R Gomis
Journal:  Lancet Oncol       Date:  2017-10-13       Impact factor: 41.316

Review 5.  The use of adjuvant bisphophonates in the treatment of early-stage breast cancer.

Authors:  Aju Mathew; Adam M Brufsky
Journal:  Clin Adv Hematol Oncol       Date:  2014-11

6.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment.

Authors:  I J Diel; E F Solomayer; S D Costa; C Gollan; R Goerner; D Wallwiener; M Kaufmann; G Bastert
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245

Review 7.  St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment.

Authors:  Marija Balic; Christoph Thomssen; Rachel Würstlein; Michael Gnant; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2019-04-04       Impact factor: 2.860

Review 8.  Bisphosphonates in breast cancer.

Authors:  Aju Mathew; Adam Brufsky
Journal:  Int J Cancer       Date:  2014-05-20       Impact factor: 7.396

9.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

10.  Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026].

Authors:  Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis
Journal:  Breast Cancer Res       Date:  2006-03-15       Impact factor: 6.466
View more
  2 in total

1.  MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice.

Authors:  Alexander H G Paterson; Peter C Lucas; Stewart J Anderson; Eleftherios P Mamounas; Adam Brufsky; Luis Baez-Diaz; Karen M King; Thomas Lad; André Robidoux; Melanie Finnigan; Miguel Sampayo; Juan Carlos Tercero; Joël Jean Mairet; Antonio C Wolff; Louis Fehrenbacher; Norman Wolmark; Roger R Gomis
Journal:  JNCI Cancer Spectr       Date:  2021-05-28

2.  Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.

Authors:  Gábor Rubovszky; Judit Kocsis; Katalin Boér; Nataliya Chilingirova; Magdolna Dank; Zsuzsanna Kahán; Dilyara Kaidarova; Erika Kövér; Bibiana Vertáková Krakovská; Károly Máhr; Bela Mriňáková; Béla Pikó; Ivana Božović-Spasojević; Zsolt Horváth
Journal:  Pathol Oncol Res       Date:  2022-07-11       Impact factor: 2.874
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.